Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α von Biziotis, Olga‐Demetra, Tsakiridis, Evangelia Evelyn, Ali, Amr, Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Mekhaeil, Bassem, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Abdulkarim, Bassam, Sur, Ranjan K., Mesci, Aruz, Ellis, Peter, Berg, Tobias, Bramson, Jonathan L, Muti, Paola, Steinberg, Gregory R, Tsakiridis, Theodoros

Volltext

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses von Tsakiridis, Evangelia E., Broadfield, Lindsay, Marcinko, Katarina, Biziotis, Olga-Demetra, Ali, Amr, Mekhaeil, Bassem, Ahmadi, Elham, Singh, Kanwaldeep, Mesci, Aruz, Zacharidis, Panayiotis G., Anagnostopoulos, Alexander E., Berg, Tobias, Muti, Paola, Steinberg, Gregory R., Tsakiridis, Theodoros

Volltext

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy von Ali, Amr, Mekhaeil, Bassem, Biziotis, Olga-Demetra, Tsakiridis, Evangelia E., Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Mesci, Aruz, Liu, Stanley, Berg, Tobias, Bramson, Jonathan L., Steinberg, Gregory R., Tsakiridis, Theodoros

Volltext

Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy von Di Pastena, Fiorella, Pond, Gregory, Tsakiridis, Evangelia E, Gouveia, Andre, Ahmadi, Elham, Biziotis, Olga-Demetra, Ali, Amr, Swaminath, Anand, Okawara, Gordon, Ellis, Peter M, Abdulkarim, Bassam, Ahmed, Naseer, Robinson, Andrew, Roa, Wilson, Valdes, Mario, Kavsak, Peter, Wierzbicki, Marcin, Wright, James, Steinberg, Gregory, Tsakiridis, Theodoros

Volltext

18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer von Mesci, Aruz, Ahmadi, Elham, Ali, Amr, Gouran-Savadkoohi, Mohammad, Evelyn Tsakiridis, Evangelia, Biziotis, Olga-Demetra, Chow, Tom, Kapoor, Anil, Sur, Monalisa, Steinberg, Gregory R., Liu, Stanley, Zukotynski, Katherine, Tsakiridis, Theodoros

Volltext

40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy von Biziotis, Olga-Demetra, Tsakiridis, Evangelia - Evelyn, Broadfield, Lindsay, Farrell, Thomas, Menjolian, Gabe, Mathurin, Tammy, Mekhaeil, Bassem, Zacharidis, Panagiotis, Muti, Paola, Abdulkarim, Bassam, Steinberg, Gregory, Tsakiridis, Theodoros

Volltext

167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy von Mekhaeil, Bassem, Zacharidis, Panagiotis, Tsakiridis, Evelyn, Biziotis, Olga-Demetra, Broadfield, Lindsay, Menjolian, Gabe, Mathurin, Tammy, Farrell, Thomas, Muti, Paola, Liu, Stanley, Steinberg, Gregory, Tsakiridis, Theodoros

Volltext

18 F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer von Mesci, Aruz, Ahmadi, Elham, Ali, Amr, Gouran-Savadkoohi, Mohammad, Evelyn Tsakiridis, Evangelia, Biziotis, Olga-Demetra, Chow, Tom, Kapoor, Anil, Sur, Monalisa, Steinberg, Gregory R, Liu, Stanley, Zukotynski, Katherine, Tsakiridis, Theodoros

Volltext